When you take two or more drugs, there is a chance that it would be the interaction between them. Interaction may increase or decrease the effectiveness of drugs or drug side-effects. The probability of drug interactions with increasing number of drugs taken increases. Therefore, people who take several drugs are in most danger. The survey focuses on the interaction of drugs and ways to avoid them.
Continue reading Drug Interactions
Older patients treated with the diabetes medications known as thiazolidinediones (which include rosiglitazone) had a significantly increased risk of heart attack, congestive heart failure and death, compared with the use of other hypoglycemic drugs, according to a study. The authors suggest that these results provide further evidence that this class of medication may cause more harm than good.
The thiazolidinediones (TZDs) rosiglitazone and pioglitazone are oral hypoglycemic agents used to treat type 2 diabetes and have been shown to improve glycemic control. While improved glycemic control has been linked to better clinical outcomes in diabetes and TZDs have been suggested as having potential cardiovascular benefits, recent concerns have arisen regarding adverse cardiac effects of these drugs.
The study, which looked at the long-term effectiveness of anti-obesity medications, found that three drugs recommended for long-term use – orlistat, sibutramine and rimonabant, reduced weight by less than 5kg (11 pounds). This equated to a loss of less than 5% of total body weight. Guidelines from the National Institute for Clinical Excellence recommend stopping the use of anti-obesity drugs if 5% of total body weight is not lost after three months
While making changes to lifestyle and diet are recommended as the initial treatment for obesity, the use of anti-obesity drugs is common.
Current UK guidelines recommend using drug therapy in addition to making lifestyle changes if a patient has a body mass index of greater than 30.
The Canadian researchers reviewed the evidence from thirty placebo-controlled trials where adults took anti-obesity drugs for a year or longer. The mean weight of the volunteers in all of the trials was 100kg (15.7 stone). The mean body mass index levels were 35 â€“ 36.
The health benefits associated with taking the drugs varied. For example, orlistat reduced the incidence of diabetes in one trial and all three drugs lowered patients levels of certain types of cholesterol. Adverse effects were recorded with all three drugs, in particular, rimonabant increased the risk of mood disorders such as depression or anxiety.
The company that markets LEVAQUIN in the U.S.,
presented the data during a scientific session that a short course of five
LEVAQUIN (levofloxacin) 750 mg tablets
administered once-daily for five days is as effective as standard therapy
of ciprofloxacin (400/500 mg) for 10 days for the treatment of complicated
urinary tract infections and acute pyelonephritis.
LEVAQUIN is available in 250
mg, 500 mg and 750 mg doses in both oral and I.V. formulations.
Since its introduction in 1996, LEVAQUIN has gained widespread use
in the treatment for a variety of bacterial infections caused by
susceptible pathogens, such us chronic bacterial prostatitis, urinary tract infections
and acute pyelonephritis (mild to moderate) acute bacterial sinusitis, nosocomial pneumonia, acute
bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, complicated and uncomplicated skin and skin
structure infections .